Cerus Corporation - Asset Resilience Ratio
Cerus Corporation (CERS) has an Asset Resilience Ratio of 28.36% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Cerus Corporation total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Cerus Corporation's Asset Resilience Ratio has changed over time. See Cerus Corporation book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cerus Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Cerus Corporation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $62.92 Million | 28.36% |
| Total Liquid Assets | $62.92 Million | 28.36% |
Asset Resilience Insights
- Very High Liquidity: Cerus Corporation maintains exceptional liquid asset reserves at 28.36% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cerus Corporation Industry Peers by Asset Resilience Ratio
Compare Cerus Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055 |
Medical Devices | 4.92% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 22.31% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.39% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Nova EYE Medical Ltd
AU:EYE |
Medical Devices | 11.08% |
Annual Asset Resilience Ratio for Cerus Corporation (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Cerus Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.36% | $62.92 Million | $221.86 Million | -1.60pp |
| 2024-12-31 | 29.96% | $60.19 Million | $200.92 Million | +2.54pp |
| 2023-12-31 | 27.41% | $54.20 Million | $197.75 Million | -3.11pp |
| 2022-12-31 | 30.52% | $66.57 Million | $218.09 Million | -3.41pp |
| 2021-12-31 | 33.94% | $80.60 Million | $237.50 Million | -9.87pp |
| 2020-12-31 | 43.81% | $97.00 Million | $221.41 Million | +13.16pp |
| 2019-12-31 | 30.65% | $50.73 Million | $165.53 Million | -23.63pp |
| 2018-12-31 | 54.28% | $88.72 Million | $163.46 Million | +6.42pp |
| 2017-12-31 | 47.85% | $47.01 Million | $98.24 Million | +0.43pp |
| 2016-12-31 | 47.42% | $49.07 Million | $103.48 Million | +20.99pp |
| 2015-12-31 | 26.43% | $36.86 Million | $139.47 Million | -8.44pp |
| 2014-12-31 | 34.87% | $28.51 Million | $81.77 Million | +1.06pp |
| 2013-12-31 | 33.81% | $28.19 Million | $83.38 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $48.92 Million | -- |
| 2011-12-31 | 0.63% | $287.00K | $45.37 Million | -1.57pp |
| 2010-12-31 | 2.20% | $1.06 Million | $48.17 Million | -5.46pp |
| 2009-12-31 | 7.67% | $2.64 Million | $34.49 Million | -18.26pp |
| 2008-12-31 | 25.93% | $12.28 Million | $47.34 Million | -21.67pp |
| 2007-12-31 | 47.60% | $37.23 Million | $78.21 Million | +6.90pp |
| 2006-12-31 | 40.69% | $47.13 Million | $115.82 Million | -27.54pp |
| 2005-12-31 | 68.23% | $40.02 Million | $58.66 Million | +13.21pp |
| 2004-12-31 | 55.02% | $56.16 Million | $102.08 Million | -18.29pp |
| 2003-12-31 | 73.31% | $86.84 Million | $118.46 Million | +15.89pp |
| 2002-12-31 | 57.42% | $41.88 Million | $72.95 Million | +11.45pp |
| 2001-12-31 | 45.97% | $58.96 Million | $128.26 Million | +26.44pp |
| 2000-12-31 | 19.53% | $18.39 Million | $94.16 Million | -68.75pp |
| 1999-12-31 | 88.28% | $36.90 Million | $41.80 Million | -- |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more